River & Mercantile Asset Management LLP acquired a new stake in BioDelivery Sciences International, Inc. (NASDAQ:BDSI) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 399,923 shares of the specialty pharmaceutical company’s stock, valued at approximately $1,860,000. River & Mercantile Asset Management LLP owned approximately 0.45% of BioDelivery Sciences International at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in the company. United Services Automobile Association raised its holdings in shares of BioDelivery Sciences International by 125.1% in the 2nd quarter. United Services Automobile Association now owns 333,209 shares of the specialty pharmaceutical company’s stock valued at $1,549,000 after purchasing an additional 185,200 shares in the last quarter. Nuveen Asset Management LLC acquired a new stake in shares of BioDelivery Sciences International in the 2nd quarter valued at $2,358,000. Jane Street Group LLC raised its holdings in shares of BioDelivery Sciences International by 967.3% in the 2nd quarter. Jane Street Group LLC now owns 274,282 shares of the specialty pharmaceutical company’s stock valued at $1,275,000 after purchasing an additional 248,584 shares in the last quarter. Citadel Advisors LLC raised its holdings in shares of BioDelivery Sciences International by 73.2% in the 2nd quarter. Citadel Advisors LLC now owns 293,112 shares of the specialty pharmaceutical company’s stock valued at $1,363,000 after purchasing an additional 123,852 shares in the last quarter. Finally, Vanguard Group Inc. raised its holdings in shares of BioDelivery Sciences International by 30.5% in the 2nd quarter. Vanguard Group Inc. now owns 3,395,428 shares of the specialty pharmaceutical company’s stock valued at $15,788,000 after purchasing an additional 793,179 shares in the last quarter. Institutional investors and hedge funds own 68.51% of the company’s stock.

NASDAQ:BDSI traded up $0.04 during midday trading on Wednesday, hitting $4.80. 41,265 shares of the company were exchanged, compared to its average volume of 875,256. The company has a fifty day simple moving average of $4.50 and a 200 day simple moving average of $4.50. BioDelivery Sciences International, Inc. has a fifty-two week low of $2.80 and a fifty-two week high of $5.37. The company has a current ratio of 2.34, a quick ratio of 2.09 and a debt-to-equity ratio of 0.88. The company has a market capitalization of $427.92 million, a PE ratio of -6.57 and a beta of 0.33.

BioDelivery Sciences International (NASDAQ:BDSI) last announced its quarterly earnings results on Thursday, August 8th. The specialty pharmaceutical company reported $0.06 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.06) by $0.12. BioDelivery Sciences International had a negative net margin of 34.73% and a negative return on equity of 0.85%. The firm had revenue of $29.68 million for the quarter, compared to analyst estimates of $25.30 million. As a group, equities research analysts expect that BioDelivery Sciences International, Inc. will post -0.12 EPS for the current year.

A number of equities research analysts have recently weighed in on BDSI shares. ValuEngine lowered shares of BioDelivery Sciences International from a “sell” rating to a “strong sell” rating in a report on Wednesday, October 2nd. William Blair restated a “buy” rating on shares of BioDelivery Sciences International in a report on Tuesday, September 17th. Finally, BidaskClub upgraded shares of BioDelivery Sciences International from a “sell” rating to a “hold” rating in a report on Monday, August 12th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $6.20.

In related news, Director Francis E. Odonnell, Jr. sold 8,000 shares of BioDelivery Sciences International stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $4.29, for a total transaction of $34,320.00. Following the sale, the director now directly owns 588,754 shares in the company, valued at approximately $2,525,754.66. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Mark A. Sirgo sold 24,506 shares of BioDelivery Sciences International stock in a transaction on Thursday, September 19th. The stock was sold at an average price of $4.79, for a total transaction of $117,383.74. Following the sale, the director now owns 1,874,637 shares in the company, valued at $8,979,511.23. The disclosure for this sale can be found here. Insiders have sold a total of 205,683 shares of company stock worth $969,862 over the last quarter. 8.94% of the stock is owned by company insiders.

About BioDelivery Sciences International

BioDelivery Sciences International, Inc, a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive drug delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies.

See Also: What is the price-to-earnings growth (PEG) ratio?

Want to see what other hedge funds are holding BDSI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioDelivery Sciences International, Inc. (NASDAQ:BDSI).

Institutional Ownership by Quarter for BioDelivery Sciences International (NASDAQ:BDSI)

Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.